SE8400788L - Nya adenosinreceptorantagonister - Google Patents

Nya adenosinreceptorantagonister

Info

Publication number
SE8400788L
SE8400788L SE8400788A SE8400788A SE8400788L SE 8400788 L SE8400788 L SE 8400788L SE 8400788 A SE8400788 A SE 8400788A SE 8400788 A SE8400788 A SE 8400788A SE 8400788 L SE8400788 L SE 8400788L
Authority
SE
Sweden
Prior art keywords
receptor antagonists
new
adenosin
adenosin receptor
phenylxanthines
Prior art date
Application number
SE8400788A
Other languages
English (en)
Other versions
SE456680B (sv
SE8400788D0 (sv
Inventor
S H Snyder
J W Daly
R F Bruns
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SE8400788D0 publication Critical patent/SE8400788D0/sv
Publication of SE8400788L publication Critical patent/SE8400788L/sv
Publication of SE456680B publication Critical patent/SE456680B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8400788A 1983-02-18 1984-02-14 Derivat av 8-fenylxantin SE456680B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/467,894 US4593095A (en) 1983-02-18 1983-02-18 Xanthine derivatives

Publications (3)

Publication Number Publication Date
SE8400788D0 SE8400788D0 (sv) 1984-02-14
SE8400788L true SE8400788L (sv) 1984-08-19
SE456680B SE456680B (sv) 1988-10-24

Family

ID=23857582

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8400788A SE456680B (sv) 1983-02-18 1984-02-14 Derivat av 8-fenylxantin

Country Status (10)

Country Link
US (1) US4593095A (sv)
JP (1) JPS59205377A (sv)
BE (1) BE898946A (sv)
CA (1) CA1234804A (sv)
DE (1) DE3406275A1 (sv)
FR (1) FR2541281B1 (sv)
GB (2) GB8403574D0 (sv)
IT (1) IT1196031B (sv)
NL (1) NL8400514A (sv)
SE (1) SE456680B (sv)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US5017577A (en) * 1986-04-25 1991-05-21 Burroughs Wellcome Co. Methods for treating viral infection
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
JPS63154687A (ja) * 1986-11-13 1988-06-27 マリオン・ラボラトリーズ・インコーポレーテッド ８ーアリールキサンチン
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (sv) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
DE60026559T2 (de) * 1999-10-29 2006-12-14 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen essstörungen
CA2439222C (en) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CN100467469C (zh) 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
IL158214A0 (en) * 2002-02-01 2004-05-12 King Pharmaceuticals Res & Dev 8-heteroaryl xanthine adenosine a2b receptor antagonists
EP1524984A1 (en) * 2002-07-29 2005-04-27 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
PT1789053E (pt) * 2004-09-01 2012-08-09 Gilead Sciences Inc Método de cicatrização de feridas utilizando antagonistas dos receptores de adenosina a2b
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
NZ570239A (en) 2006-02-03 2011-09-30 Gilead Palo Alto Inc Preparation of (1-{ 9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl} pyrazol-4-yl)-N-methylcarboxamide monohydrate
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
CN102164591A (zh) * 2008-09-29 2011-08-24 吉利德科学股份有限公司 速率控制剂和A-2-α受体拮抗剂的组合用于多检测器计算机化断层显像方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2840559A (en) * 1954-06-22 1958-06-24 Krantz Jr Nuclearly substituted 8-theophyllines and method of making the same
DE1091570B (de) * 1958-10-23 1960-10-27 Albert Ag Chem Werke Verfahren zur Herstellung von in 8-Stellung substituierten 1, 3-Dialkylxanthinen
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
NL297352A (sv) * 1962-08-31
EP0011399A1 (en) * 1978-11-11 1980-05-28 FISONS plc N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines

Also Published As

Publication number Publication date
FR2541281A1 (fr) 1984-08-24
GB2135311A (en) 1984-08-30
FR2541281B1 (fr) 1988-01-29
DE3406275A1 (de) 1984-09-27
NL8400514A (nl) 1984-09-17
SE456680B (sv) 1988-10-24
IT1196031B (it) 1988-11-10
JPS59205377A (ja) 1984-11-20
GB8403574D0 (en) 1984-03-14
GB8404243D0 (en) 1984-03-21
BE898946A (fr) 1984-06-18
GB2135311B (en) 1986-11-05
SE8400788D0 (sv) 1984-02-14
CA1234804A (en) 1988-04-05
IT8419675A0 (it) 1984-02-17
US4593095A (en) 1986-06-03

Similar Documents

Publication Publication Date Title
SE8400788L (sv) Nya adenosinreceptorantagonister
FI832521L (fi) Nya n-(bicykliska heterocyklyl)-4-piperidinaminer
FI840547A (fi) Nya farmakologiskt aktiva foereningar.
FI840824A (fi) Nya azol-foereningar.
FI822643A0 (fi) Dihydropyridiner med positiv inotrop verkan, nya foereningar, deras anvaendning i laekemedel och foerfarande foer deras framstaellning
NO872871D0 (no) Ruteholder for glassfasader.
IT8820190A0 (it) Pilone per aereo.
NO851516L (no) Krysstang-kvadrupolkilde for akustisk broennlogging.
FI833859A0 (fi) Nya azolfoereningar
FI853171A0 (fi) Nya guaninderivat.
FI872808A (fi) Nya topiskt applicerbara farmaceutiska sammansaettningar med systemisk verkan.
FI834131A0 (fi) Nya derivat av tricykliska aminosyror, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning, samt nya bicykliska aminosyror saosom mellanskeden och foerfarande foderas framstaellning
FI833300A0 (fi) Nya farmakologiska blandningar, som baserar sig pao cisplatina samt foerfarande foer framstaellningdesamma
FI840968A0 (fi) Nya azoler, deras framstaellningsprocesser och deras anvaendning
FI832602A (fi) Nya 2-aza-bicyklo/2,2,2/oktan-3-karbonsyraderivat, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning, samt aza-bicyklo/2,2,2/oktan-3-karbonsyra saosom mellanprodukt och foerfaranden foer deras framstaellning
FI840867A (fi) Nya karboxamider.
FI845064L (fi) Nya pyrrolin orto-kondenserade derivat, deras framstaellning och dessa innehaollande laekemedel.
FI832556A0 (fi) Nya 19-tio-androstanderivat
IT8467449A1 (it) Procedimento per ottenere vetro piano ricoperto.
FI844466A0 (fi) Nya amidfoereningar.
FI843332A0 (fi) Nya pesticidala heterocykliska foereningar.
FI833162A (fi) Nya oktahydrobenz/f/isokinoliner beroerande eller foerbaettringar betraeffande dessa
ES523724A0 (es) Procedimiento de obtencion de fosfinamidas con efectos antitumorales.
FI833480A (fi) Nya antracyklinglykosider
FI834481A (fi) Nya etenamidin- och guanidinderivat.

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8400788-9

Effective date: 19940910

Format of ref document f/p: F